Literature DB >> 26770154

Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 1.

Khara Lucius1, Kristen Trukova1.   

Abstract

The cardiovascular toxicities of breast cancer treatment are important health problems, with potential public health consequences. Integrative therapies may represent important tools for prevention in this population. This article reviews the cardiotoxicity of conventional breast cancer therapy, including chemotherapy, radiation, and hormonal therapy. Data are presented on the benefits of substances such as curcumin, melatonin, Ginkgo biloba, resveratrol, coenzyme Q10, and l-carnitine. Although clinical studies on many of these substances are limited both in size and number, preclinical studies are available for several, and this article summarizes the potential mechanisms of action. Areas for future research are also identified.

Entities:  

Year:  2015        PMID: 26770154      PMCID: PMC4712857     

Source DB:  PubMed          Journal:  Integr Med (Encinitas)        ISSN: 1546-993X


  67 in total

1.  Docetaxel induced cardiotoxicity.

Authors:  M Shimoyama; Y Murata; K I Sumi; R Hamazoe; I Komuro
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

2.  Trastuzumab-induced cardiac dysfunction: A 'dual-hit'.

Authors:  Matthew Zeglinski; Ana Ludke; Davinder S Jassal; Pawan K Singal
Journal:  Exp Clin Cardiol       Date:  2011

3.  [Effect of resveratrol on heart function of rats with adriamycin-induced heart failure].

Authors:  Gui-ying Wang; Yong-mei Wang; Li-nan Zhang; Qian Li; Hua Yue; Cui-miao Song; Jing-kun Feng; Na Wang
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2007-08

4.  Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.

Authors:  Dawn L Hershman; Russell B McBride; Andrew Eisenberger; Wei Yann Tsai; Victor R Grann; Judith S Jacobson
Journal:  J Clin Oncol       Date:  2008-07-01       Impact factor: 44.544

5.  Deaths: final data for 2010.

Authors:  Sherry L Murphy; Jiaquan Xu; Kenneth D Kochanek
Journal:  Natl Vital Stat Rep       Date:  2013-05-08

6.  Risk of ischemic heart disease in women after radiotherapy for breast cancer.

Authors:  Sarah C Darby; Marianne Ewertz; Paul McGale; Anna M Bennet; Ulla Blom-Goldman; Dorthe Brønnum; Candace Correa; David Cutter; Giovanna Gagliardi; Bruna Gigante; Maj-Britt Jensen; Andrew Nisbet; Richard Peto; Kazem Rahimi; Carolyn Taylor; Per Hall
Journal:  N Engl J Med       Date:  2013-03-14       Impact factor: 91.245

7.  Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients.

Authors:  C L Shapiro; P H Hardenbergh; R Gelman; D Blanks; P Hauptman; A Recht; D F Hayes; J Harris; I C Henderson
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

8.  Cardiotoxicity associated with high-dose cyclophosphamide therapy.

Authors:  J S Gottdiener; F R Appelbaum; V J Ferrans; A Deisseroth; J Ziegler
Journal:  Arch Intern Med       Date:  1981-05

9.  Effects of curcuminoids on frequency of acute myocardial infarction after coronary artery bypass grafting.

Authors:  Wanwarang Wongcharoen; Sasivimon Jai-Aue; Arintaya Phrommintikul; Weerachai Nawarawong; Surin Woragidpoonpol; Thitipong Tepsuwan; Apichard Sukonthasarn; Nattayaporn Apaijai; Nipon Chattipakorn
Journal:  Am J Cardiol       Date:  2012-04-03       Impact factor: 2.778

10.  Protective effect of melatonin against Adriamycin-induced cardiotoxicity.

Authors:  Yan Zhang; Lixin Li; Cheng Xiang; Zhiqian Ma; Tian Ma; Shuchai Zhu
Journal:  Exp Ther Med       Date:  2013-03-06       Impact factor: 2.447

View more
  2 in total

Review 1.  Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors:  Ping-Pin Zheng; Jin Li; Johan M Kros
Journal:  Med Res Rev       Date:  2017-09-01       Impact factor: 12.944

2.  NRSN2 promotes breast cancer metastasis by activating PI3K/AKT/mTOR and NF-κB signaling pathways.

Authors:  Fei Ren; Wei Zhang; Shuai Lu; Hong Ren; Yantong Guo
Journal:  Oncol Lett       Date:  2019-11-28       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.